

Mirzotamab Biosimilar - Research Grade

Product Code: ICH5687

More Information

Species Reactivity: Human

Target: CD276

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Mirzotamab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q5ZPR3

Shipping Conditions: Blue ice

background: B7-H3 (CD276) is an immune-checkpoint molecule broadly overexpressed on solid tumors yet limited on normal tissue, making it an attractive antigen in cancer immunology. We offer an unconjugated, non-therapeutic analog of mirzotamab as a recombinant human IgG1 kappa antibody against CD276, strictly for research use only (RUO). The reagent is purified to low endotoxin so it can be deployed in vivo, and it is produced in scalable milligram-to-gram lots that accommodate heavy-usage and high-throughput laboratories. It supports binding and functional assays, in vitro screening, ADCC studies, preclinical tumor models, and antibody-drug-conjugate development.

Other names: B7-H3, B7H3

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks